Syndax Announces Participation in February Investor Conferences

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its participation in two upcoming investor conferences in February 2025. CEO Michael A. Metzger and the management team will attend:

1. The Guggenheim SMID Cap Biotech Conference in New York, featuring a fireside chat on February 6, 2025, at 10:30 a.m. ET

2. Citi's 2025 Virtual Oncology Leadership Summit, with a fireside chat scheduled for February 19, 2025, at 9:00 a.m. ET

Both presentations will be available via webcast on the company's website investor section, with replays accessible for a time.

News Market Reaction – SNDX

-0.21%

-0.21% Session move

In the trading session that priced this news, SNDX declined 0.21%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025, at 10:30 a.m. ET
• Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025, at 9:00 a.m. ET

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-in-february-investor-conferences-302363686.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When is Syndax (SNDX) presenting at the Guggenheim SMID Cap Biotech Conference in 2025?

Syndax (SNDX) will present at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET in New York.

When is Syndax (SNDX) participating in Citi's 2025 Virtual Oncology Leadership Summit?

Syndax (SNDX) will participate in Citi's 2025 Virtual Oncology Leadership Summit on February 19, 2025, at 9:00 a.m. ET.

Where can investors watch Syndax's (SNDX) February 2025 conference presentations?

Investors can watch the webcasts of Syndax's presentations in the Investor section of the company's website at www.syndax.com, where replays will also be available for a time.

Which Syndax (SNDX) executives are participating in the February 2025 investor conferences?

CEO Michael A. Metzger and members of the Syndax management team will participate in the February 2025 investor conferences.